Helix Acquisition Corp. III Class A Ordinary Shares(HLXC)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$10.29
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for HLXC

11/13/2026: HLXC (1-star) is currently NOT-A-BUY. Pass it for now.

Helix Acquisition Corp. III is a special purpose acquisition company formed to pursue a merger or business combination within the biotechnology, medical technology, and life sciences sectors. The company's main strength lies in its experienced management team and $172.5 million in trust capital secured during its January 2026 initial public offering. Its primary investment story centers on the opportunity to participate in taking an innovative private healthcare company public. However, key risks include the lack of active operations, execution uncertainty, and the mandatory deadline to complete a deal or face liquidation. The stock is best suited for speculative or event-driven investors monitoring merger announcements and trust redemption dynamics.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitThe company currently lacks active business operations or revenue growth until a merger is completed.
Momentum investorStrong fit while signal remains positiveMomentum fit is conditional on a positive Upturn signal driven by announcement news or market speculation regarding a target.
Value investorMixed fitShares often trade close to the net trust redemption value, offering asset backing but no fundamental earnings value.
Dividend investorWeak fitThe company pays no dividends and offers no recurring income distribution.
Low-risk investorMixed fitWhile trust account structures provide a structural price floor near $10.00, pre-deal SPACs carry execution and opportunity risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityLowPre-deal SPAC shares typically trade tightly around their cash-in-trust redemption value before an acquisition announcement.
Valuation riskMediumInvestors face uncertainty regarding the valuation and future fundamentals of any target company chosen for combination.
Competition risk (healthcare SPAC competition)Medium / highThe company competes with numerous other blank check vehicles for attractive life sciences acquisition targets.
Business qualityLow / noneThe company has no underlying commercial business operations or product franchise at this stage.
Dividend incomeLow / noneNo dividend distributions are paid to ordinary shareholders.
Execution riskHighSuccess depends entirely on management's ability to locate, negotiate, and consummate a successful business combination within the required timeframe.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 227.00M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 43.6K shares
Beta -
52 Weeks Range 10.00 - 11.23
Updated Date 11/15/2026
52 Weeks Range 10.00 - 11.23
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -

Sector & Industry Intelligence

Sector

Financial Services

Constructive
Sentiment
Bullish
Momentum
BUY Breadth Improving
BUY participation
50.4%
Active BUY / eligible
61 / 121
30-Day BUY Count Change
+45
Market state
Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Shell Companies

BUY participation
100.0%
Active BUY / eligible
1 / 1
30-Day BUY Count Change
+1

Eligible universe: 1 stock.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steady Uptrend
PRICE PATH

Steady Uptrend

The stock demonstrates consistent and steady upward price momentum.

Smooth
PRICE STABILITY

Smooth

The stock has moved along a generally orderly path with only modest fluctuations.

Analysis of Past Performance

Type Stock
Historic Profit -2.04%
Avg. Invested days 36
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
HLXC receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
HLXC has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. Growth and ownership metrics are mixed: slightly negative earnings growth (+0.0%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
HLXC's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
HLXC's growth profile is soft, with the least-weak measure being revenue growth at +0.0% year over year. By comparison, while earnings growth (+0.0%, slightly negative) and free-cash-flow growth (+0.0%, slightly negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 99.0% and approximately 59.3% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.35%, which materially reduces the ownership score.

Top 5 Institutional Investors

Nantahala Capital Management, LLC 11.33%
Cormorant Asset Management, LLC 5.88%
Affinity Asset Advisors, LLC 5.67%
RA Capital Management, LLC 5.67%
SILVERARC CAPITAL MANAGEMENT, LLC 5.34%

Unit Economics (Per $1K Revenue)

★★★★★
HLXC generates approximately $0 of gross profit, $-0 of operating income, and $0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
HLXC has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Trust Account InterestInterest income generated from cash proceeds held in U.S. government securities and money market funds within the trust account.The company does not make money from selling products or services; earnings come primarily from interest on cash held in trust.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 227.09M
Price to Sales(TTM) -
Enterprise Value 227.09M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 17.75M
Shares Floating 10.52M
Shares Outstanding 17.75M
Shares Floating 10.52M
Percent Insiders 0.35
Percent Institutions 98.95

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.